Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , each with Trodelvy® as First-Line Treatment of PD-L1+ Advanced Triple-Negative Breast Cancer
European Commission Approves KEYTRUDA® Plus Padcev® as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis
U.S. FDA Approves an Additional Indication for CAPVAXIVE® in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each With WELIREG® , for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation for Calderasib , an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer
